促红细胞生成素治疗肿瘤相关性慢性贫血患者的疗效

目的 观察促红细胞生成素治疗肿瘤相关性慢性贫血患者的疗效，探讨其临床价值。 方法 选择台州市第一人民医院于2012年2月—2016年2月收治的80例肿瘤相关性慢性贫血患者入选本研究，均符合诊断标准，无明显药物禁忌，按照随机数字表随机分为2组，每组40例。对照组在常规治疗基础上采用静脉滴注蔗糖铁治疗，观察组在常规治疗基础上给予皮下注射促红细胞生成素治疗，比较2组血液指标变化、KPS评分疗效、血液学指标疗效和不良反应。 结果 治疗后，观察组血各液学指标改善情况明显优于照组，差异有统计学意义(P＜0.05)；2组患者治疗后KPS量表评分疗效总有效率观察组明显优于对照组，差异有统计学意义(P＜0.05)；治疗后观察组有效率为95.0%，对照组有效率为47.5%，观察组有效率明显高于对照组，差异有统计学意义(P＜0.05)。观察组总不良反应发生为12.50%，显著低于对照组37.50%，差异有统计学意义(P＜0.05)。 结论 促红细胞生成素治疗肿瘤相关性贫血疗效确切，不良反应相对较少，值得临床推广应用。 

Clinical efficacy of erythropoietin in the treatment of patients with cancer-related anemia

Objective To investigate the clinical efficacy and mechanism of erythropoietin in the treatment of patients with cancer-related anemia. Methods In our hospital,from February,2012 to February,2016,80 cases of tumor associated chronic anemia patients enrolled in this study.All met the diagnostic criteria and no obvious contraindications were randomly divided into two groups according to random number table,each group of 40 cases.The control group received intravenous drip of sucrose iron in the treatment of regular treatment,while the observation group received subcutaneous injection of erythropoietin therapy on the basis of routine treatment.The blood index changes,KPS score curative effect,hematology index curative effect and adverse reaction were compared between the two groups. Results After treatment,the improvement of blood flow in the observation group was significantly better than the control group(P<0.05).The total effective rate of two groups of patients after treatment KPS scale score was significantly better than the control group(P<0.05).After treatment,the effective rate of the observation group was 95%,the effective rate of the control group was 47.5%,the observation group was significantly higher than that of the control group(P<0.05).The total adverse reactions in the observation group were 12.50%,significantly lower than the control group of 37.50%,and the difference was statistically significant (P<0.05).The total adverse reactions in the observation group were 12.50%, significantly lower than the control group of 37.50%, and the difference was statistically significant (P<0.05). Conclusion In the treatment of anemia associated with tumor curative effect,erythropoietin has less adverse reactions,worthy of clinical application.